Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 4/20 | 0.47 |
| ▸ | RXRB | P28702 | 4/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547348 | 0.86 | PDCD1 (0.57) | PDCD1CD274RXRARXRBBCL2 | |
| SCHEMBL6547138 | 0.85 | PDCD1 (0.50) | PDCD1CD274RXRARXRBBCL2 | |
| SCHEMBL6227986 | 0.81 | MAPT (0.57) | PDCD1CD274RXRARXRBMAPT | |
| SCHEMBL28001194 | 0.80 | ALDH1A1 (0.44) | MAPT | |
| SCHEMBL560460 | 0.79 | TSHR (0.53) | PDCD1CD274SMN1; SMN2 | |
| SCHEMBL14690351 | 0.79 | TSHR (0.53) | PDCD1CD274SMN1; SMN2 | |
| SCHEMBL12393850 | 0.79 | PDCD1 (0.55) | PDCD1CD274MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6563516 | 0.79 | PDCD1 (0.48) | PDCD1CD274RXRARXRBBCL2 | |
| SCHEMBL6393405 | 0.78 | ALDH1A1 (0.54) | PDCD1CD274MAPT | |
| SCHEMBL6389397 | 0.78 | ALDH1A1 (0.54) | PDCD1CD274MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730371-B2 | LIQUID CRYSTAL DISPLAY | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-05-04 | — | — | US | disclosed |
| EP-1249484-B1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL CO (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-20030054119-A1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL CO., INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1249484-A1 | Optically active compound and liquid crystal composition containing the compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054119-A1 | Optically active compound and liquid crystal composition containing the compound | HDHD5, THOC2, TDO2 | PDCD1 1767/4885CD274 2993/4885RXRA 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.